Lupin Limited has informed the exchanges that its wholly owned subsidiary in the Netherlands, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical company headquartered in Amsterdam. The deal values VISUfarma at an enterprise value of €190 million, which will be paid in cash, subject to customary adjustments at closing.
VISUfarma operates in the ophthalmology segment and has subsidiaries in the United Kingdom and Italy. The company has a presence across major European countries, including Italy, the UK, Spain, Germany and France. Its portfolio covers over sixty branded products in therapeutic areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and nutraceuticals.
For the year ended December 31, 2024, VISUfarma reported a consolidated turnover of €48.1 million and a net worth of €134.6 million. In the previous years, its turnover stood at €42.5 million in 2023 and €43.9 million in 2022.
The proposed acquisition does not fall under related party transactions, and none of Lupin’s promoter or group companies have any interest in the entity being acquired. Completion of the transaction is subject to approvals from the national authorities for foreign direct investment in Germany, along with a notification process in Spain. Lupin expects the deal to close by the end of calendar year 2025.
Nanomi B.V. will acquire one hundred percent of VISUfarma’s share capital once the required conditions are met. VISUfarma was incorporated on June 9, 2016, and maintains its commercial headquarters in Amsterdam.